AMRA-MEDICAL
10.4.2024 16:57:33 CEST | Business Wire | Press release
Researchers from AMRA Medical, a leading health informatics company providing body composition analysis through magnetic resonance imaging (MRI), together with Eli Lilly, and researchers from Nantes Université, University Hospitals Cleveland, and Linköping University used visceral-, subcutaneous-, and liver fat z-scores derived from MRI to investigate changes in fat distribution patterns in patients with type 2 diabetes (T2D) participating in SURPASS-3 MRI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410636011/en/
AMRA Medical's Personalized Fat Z-scores (Photo: Business Wire)
Absolute (or percent) change in body weight and/or BMI are still typical endpoints in clinical trials evaluating treatments for obesity and related disorders. However, the research team’s recent findings from the SURPASS-3 MRI study suggest that pharmacological treatments for T2D may alter the fat distribution pattern in various ways - independent of changes in body weight. For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.
The personalized fat z-scores were introduced through research published in 2023 linking fat distribution patterns, as described by the z-scores, to specific cardiometabolic disease risk profiles in the general population. This was quickly followed by Surgery for Obesity and Related Diseases (SOARD) publishing results on risk-stratification of obesity class I & II by the fat z-scores in the American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines/statements journal section of SOARD. (Read more about z-score use in risk-stratification here).
The current exploratory analysis of data from Lilly’s SURPASS-3 MRI study, described changes in the fat z-scores in people with T2D following treatment with once-weekly tirzepatide (5, 10 or 15 mg dose) or once-daily basal insulin degludec for 52 weeks. The results showed that treatment with tirzepatide was associated with a significant reduction in visceral fat z-score (-0.18 SD) and liver fat z-score (-0.54 SD), while the subcutaneous fat z-score increased from an initially negative value (+0.11 SD) - suggesting a therapeutically-induced shift towards a better-balanced body fat distribution with prominent visceral and liver fat loss.
During follow-up of interventions that induce weight reduction, it has been difficult to determine whether a concurrent reduction of, e.g., visceral fat was in line with the amount of weight lost, or if there was larger reduction than expected. The significant reduction of visceral fat and liver fat z-scores observed with tirzepatide in SURPASS-3 MRI indicates a potential targeted effect beyond that expected by the magnitude of weight reduction.
Read the full publication titled ‘Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes’ here.
About AMRA Medical
AMRA Medical is a health informatics company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition analysis, delivering multiple fat and muscle biomarkers with unrivalled accuracy and precision – all from a rapid whole-body MRI scan. AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410636011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 18:00:00 CET | Press release
High speed data transfers send SES’s CEO to space, advancing meoSphere optical network SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstra
Smartsheet Unveils vsActual: The AI-Native Platform that Connects Strategy to Execution at ENGAGE 20264.11.2026 18:00:00 CET | Press release
vsActual closes the gap between strategic planning and execution, connecting systems, tracking and reporting to planning, so teams and leaders can catch drift while it’s still fixable Smartsheet, the AI-powered enterprise work management platform, today unveiled a new AI-native strategic planning and execution product at ENGAGE 2026, its annual customer conference. vsActual is designed to solve the two biggest obstacles to enterprise execution: siloed work scattered across disconnected systems and teams, and the manual tracking and reporting that keeps individuals and executives from seeing problems until it’s too late. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104989965/en/ Today, Smartsheet unveiled a new AI-native strategic planning and execution product, vsActual. AI is helping individuals move faster than ever, but it's also making it harder to keep everyone moving in the same direction. In fact, a PMI research
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom